COMPEL Data Show Osimertinib Plus Chemo Beats Chemo Alone for EGFRm NSCLC Following Progression Osimertinib is a targeted treatment often used as the first option for people with non-small cell lung cancer (NSCLC) that has EGFR mutations. When the cancer